Medexus Pharmaceuticals (MDP.TO) is a rare disease pharmaceutical company with a portfolio of innovative and high value rare disease products positioning the company for growth in the next decade…
Medexus Pharmaceuticals
Medexus Pharmaceuticals (MDP.T) today announced its financial results and provided a business update for the three-month period ended June 30, 2021. “We continued to see pressure on IXINITY® ex-factory…
Medexus Pharmaceuticals (MDP.T) announced today that it has completed enrollment in its Phase 4 clinical trial of IXINITY®, targeting label expansion for pediatric hemophilia B. We are hopeful that…
Medexus Pharmaceuticals (MDP.T) announced today that medac GmbH, the Company’s licensor for treosulfan, has received a Complete Response Letter (CRL) from the Food and Drug Administration (FDA) in response…
Medexus Pharmaceuticals (MDP.T) received Health Canada’s Notice of Compliance to commercialize treosulfan today, according to a press release. Treosulfan will be sold in Canada using the brand name…
Medexus Pharmaceuticals (MDP.V) announced that they’re making their Triamcinolone Hexacetonide (TH) Injectable Suspension, USP (20 mg/ml) available in the United States through the FDA’s CDER Drug Shortage program in…